Gottfried R. Von Keudell
Advanced in Hairy Cell Leukemia (HCL)

Dr. Gottfried R. Von Keudell

Internal Medicine
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Hairy Cell Leukemia (HCL)
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gottfried Von Keudell is an Internal Medicine provider in Boston, Massachusetts. Dr. Von Keudell is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hairy Cell Leukemia (HCL).

Graduate Institution
University Medical Center Hamburg - Eppenddorf
Residency
University of Chicago Medical Center
Specialties
Internal Medicine
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Beth Israel Deaconess Medical Center
University of Chicago Medical Center
Hospital Affiliations
Beth Israel Deaconess Medical Center
Languages Spoken
English
German
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, Boston, MA 02215
Other Locations
CHA - Medical Specialties - Whidden Campus
103 Garland Street, Everett, MA 02149
Cambridge Hospital
1493 Cambridge Street, Cambridge, MA 02139

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Phase 1
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Nivolumab
Study Phase: Phase 2
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 2
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Venetoclax
Study Phase: Phase 2
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drugs: Abexinostat, Ibrutinib
Study Phase: Phase 1
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: TGR-1202, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Enrollment Status: Terminated
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

35 Total Publications

Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.
Journal: Blood advances
Published: March 18, 2025
Similar Doctors
Advanced in Hairy Cell Leukemia (HCL)
Dr. Kipp A. Weiskopf
Internal Medicine
Advanced in Hairy Cell Leukemia (HCL)
Dr. Kipp A. Weiskopf
Internal Medicine
75 Francis St, 
Boston, MA 
 (0.3 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances

Kipp Weiskopf is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Weiskopf is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Lung Metastases, Lung Cancer, and Noma.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Bimalangshu R. Dey
Internal Medicine
Advanced in Hairy Cell Leukemia (HCL)
Dr. Bimalangshu R. Dey
Internal Medicine

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English, Bengali, Hungarian
See accepted insurances
Offers Telehealth

Bimalangshu Dey is an Internal Medicine provider in Boston, Massachusetts. Dr. Dey is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Thrombocytopenia, Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant.

Advanced in Hairy Cell Leukemia (HCL)
Dr. James M. Koomey
Internal Medicine | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. James M. Koomey
Internal Medicine | Oncology

Beth Israel Deaconess Hospital - Plymouth Cancer Center

275 Sandwich Street, 
Plymouth, MA 
 (36.1 miles away)
508-830-2390
Languages Spoken:
English
See accepted insurances

James Koomey is an Internal Medicine specialist and an Oncologist in Plymouth, Massachusetts. Dr. Koomey is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Von Keudell's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile